Physician profile
Ramon V Sanchez
NPI 1063404408
$13,561.39
in general payments reported to CMS, 2019-2025
32 companies · $2,650 in 2025
The $2,650 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,163 · 2020: $785 · 2021: $2,044 · 2022: $2,437 · 2023: $2,008 · 2024: $2,474 · 2025: $2,650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,934 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,934.41 |
| Education | $197.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,362.59 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,743.57 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $1,439.54 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $1,115.75 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $1,107.68 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $879.77 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $818.60 | 2019-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $616.14 | 2019-2025 | Fanapt, Hetlioz |
| Indivior INC. | $607.17 | 2020-2024 | Perseris |
| Sunovion Pharmaceuticals INC. | $591.33 | 2019-2022 | |
| Axsome Therapeutics, INC. | $379.39 | 2024-2025 | Auvelity |
| Abbvie INC. | $315.61 | 2022-2025 | Vraylar |
| E.R. Squibb & Sons, L.L.C. | $254.54 | 2024-2025 | Cobenfy |
| Allergan, INC. | $174.12 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $172.54 | 2022-2025 | Qelbree, Qelbree |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $134.23 | 2020-2021 | |
| Tris Pharma INC | $129.33 | 2022-2025 | Onyda Xr, Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $111.82 | 2019-2024 | |
| Almatica Pharma LLC | $96.57 | 2022-2023 | Loreev Xr, Sertraline Hcl |
| Corium, LLC | $88.11 | 2022-2024 | Azstarys |
| Merck Sharp & Dohme LLC | $64.94 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $62.53 | 2019-2023 | Nuplazid |
| Noven Therapeutics, LLC | $50.11 | 2021-2025 | Secuado, Xelstrym |
| Takeda Pharmaceuticals U.S.A., INC. | $47.53 | 2022-2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $47.39 | 2022-2023 | Quviviq |
| Avanir Pharmaceuticals, INC. | $33.22 | 2019 | |
| Bausch Health US, LLC | $27.06 | 2019-2023 | Aplenzin |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.59 | 2023 | Rexulti |
| Luye Pharma (USA) LTD. | $20.78 | 2025 | Erzofri Extended-Release |
| Vertical Pharmaceuticals, LLC | $19.08 | 2024 | Relexxii |
| Collegium Pharmaceutical, INC. | $15.18 | 2025 | Jornay Pm |
| Neuronetics, INC. | $10.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramon Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.